No recent news items with business impact were identified. The company has filed recent SEC reports to become current in its reporting obligations.

• The company filed its Annual Report on Form 10-K for the year ended July 31, 2025 on January 30, 2026, and the Quarterly Report on Form 10-Q for the quarter ended October 31, 2025, becoming current in its SEC reporting obligations.[S1][S2]
• NIMS entered into promissory note amendments extending maturity dates into 2026 with related parties including Frost Gamma Investments Trust and Dr. Jane Hsiao.[S1]

The company’s existing intellectual property or prior technology platform could potentially be leveraged or revived if new capital and strategic direction are secured. Amendments to promissory notes and efforts to maintain SEC reporting compliance indicate some ongoing corporate activity that might support future restructuring or transactions.

NIMS faces substantial risks including recurring operating losses, negative working capital, and very limited liquidity. The company has substantial doubt about its ability to continue as a going concern absent additional financing. Lack of independent governance oversight and penny stock status contribute to investor risk. The absence of active operations and product sales limits business model visibility and prospects for near-term recovery.

NIMS currently lacks an active business model, products, or operations, and thus does not possess competitive advantages or economic moats. The company’s prior product offerings and technology are no longer in active development or sale, and it functions as a shell company with limited resources and governance.

• Going Concern Risk: The company has recurring losses, an accumulated deficit of $29 million, and negative working capital, raising substantial doubt about its ability to continue as a going concern without additional financing.
• Liquidity Risk: As of December 31, 2025, the company had very limited cash and current assets relative to current liabilities, with a current ratio of 0.01 and cash ratio of 0.06, indicating significant liquidity constraints.
• Operational Risk: Operations were discontinued in 2019, and the company currently has no products or inventory, effectively functioning as a shell company.
• Governance Risk: The company lacks an independent audit and compensation committee, with only one independent director who resigned in 2025, potentially compromising oversight and management accountability.
• Regulatory and Reporting Risk: The company experienced delays in SEC filings but has become current; however, future delays could negatively impact investor confidence and liquidity.
• Market and Stock Risk: The common stock is a penny stock trading on OTC Pink with low liquidity, significant price volatility, and restrictions that may limit investors' ability to sell shares.

• Non-Invasive Monitoring Systems, Inc. (NIMS) was incorporated in Florida in 1980 and is headquartered in Miami, Florida.
• The company's primary business previously involved research, development, manufacturing, marketing, and sales of non-invasive, motorized, whole body periodic acceleration (WBPA) platforms intended to aid temporary relief of minor aches and pains, muscle relaxation, and reduce morning stiffness.
• Operations were effectively discontinued in May 2019, and the company is currently a shell company as defined by SEC rules.
• NIMS currently has no inventory and no products available for sale.
• The company has a history of operating losses and has not been profitable, with net losses of $222,000 and $113,000 for fiscal years ended July 31, 2025 and 2024, respectively.
• As of July 31, 2025, the company had an accumulated deficit of approximately $29.0 million.
• The company had $3,000 in cash and negative working capital of approximately $947,000 as of July 31, 2025.
• Financial snapshot as of December 31, 2025 shows cash and equivalents of $64,000 (as of April 30, 2024), current assets of $6,000, current liabilities of $1,002,000, resulting in a current ratio of 0.01 and a cash ratio of 0.06, indicating very limited liquidity.
• The company’s consolidated financial statements have been prepared on a going concern basis with substantial doubt about its ability to continue as a going concern due to recurring losses and accumulated deficit.
• NIMS has experienced delays in filing SEC reports but has become current as of January 30, 2026.
• The company does not have an independent audit or compensation committee; governance is limited with only one independent director who resigned in August 2025.
• NIMS does not anticipate paying dividends and its common stock is classified as a penny stock trading on OTC Pink, with low liquidity and significant price volatility.
• The company has authorized 400 million shares of common stock and 1 million shares of preferred stock, with approximately 154.8 million common shares outstanding as of January 30, 2026.
• The company has issued promissory notes with related parties, including Frost Gamma Investments Trust and Dr. Jane Hsiao, with amendments extending maturity dates into 2026.